About Immunocore

Immunocore develops bispecific T cell receptor therapies to treat cancer, infectious diseases and autoimmune conditions. The company's proprietary ImmTAX technology platform engineers molecules that activate or modulate the immune system, enabling it to recognize and destroy diseased cells that would otherwise evade detection. This approach addresses critical gaps in treatment for patients with solid tumours and immune disorders. As a commercial stage biotechnology company, Immunocore delivered the world's first approved TCR therapy. The diverse pipeline spans uveal melanoma to hepatitis B and HIV. Job seekers join teams advancing medicines that radically improve patient outcomes through scientific rigour and entrepreneurial spirit.